# The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

> **NCT01923428** · PHASE2,PHASE3 · COMPLETED · sponsor: **Ardelyx** · enrollment: 356 (actual)

## Conditions studied

- Constipation Predominant Irritable Bowel Syndrome

## Interventions

- **DRUG:** AZD1722
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01923428
- **Lead sponsor:** Ardelyx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01923428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01923428, "The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01923428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*